Wave Life Sciences Taps Sanofi Exec as Chief Business Officer to Drive Growth

  • Wave Life Sciences appointed Dr. Monika Vnuk as Chief Business Officer on September 22, 2026.
  • Dr. Vnuk received a stock option to purchase 375,000 shares, vesting over four years with an exercise price of $4.25 per share.
  • Vnuk previously led global business development at Sanofi and managed late-stage product financing at Blackstone Life Sciences.
  • She negotiated the Pfizer-BioNTech COVID-19 vaccine partnership during her tenure at Pfizer.

Wave Life Sciences is bolstering its executive team with a seasoned business development leader as it advances its RNA medicines platform. Dr. Vnuk's background in high-stakes partnerships and asset financing suggests a strategic focus on scaling Wave's pipeline and securing value-creating deals. The move comes as the biotech industry increasingly turns to RNA-based therapies, positioning Wave to compete in a rapidly evolving market.

Pipeline Expansion
How Dr. Vnuk's experience will accelerate Wave's RNA medicines pipeline, particularly in obesity, liver disease, and rare disorders.
Strategic Partnerships
Whether Vnuk can replicate her success in negotiating high-value partnerships, such as the Pfizer-BioNTech deal, for Wave.
Financial Performance
The pace at which Wave can translate its differentiated RNA platform into revenue-generating transactions under Vnuk's leadership.